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Objectives: To investigate the incidence, risk factors, causative fungi, and outcomes of fungemia
in adult, non-HIV-infected patients.
Design: We studied 147 episodes of fungemia due to Candida spp and Trichosporon spp in adult
patients admitted to a university hospital in Northeast Thailand between 1999 and 2003.
Results: The overall incidence of fungemia was 14.1 per 10 000 hospital admissions. Candida was
the most common isolate (138 episodes, 93.9%) with non-albicans Candida accounting for 68.7%.
The major non-albicans Candida isolates were Candida parapsilosis and Candida tropicalis.
Fungemia caused by Trichosporon accounted for 6.1% of the cases, but their clinical features
could not be distinguished from fungemia due to Candida. The overall in-hospital mortality rate
was 56.1%. The independent factors related to mortality were high APACHE II score (odds ratio
(OR) 1.12 per 1-point increments, 95% confidence interval (CI) 1.03—1.23), assisted ventilation
(OR 3.49, 95% CI 1.04—11.64), and neutropenia (OR 7.47, 95% CI 1.25—44.74).
Conclusions: Candidemia, especially that caused by non-albicans Candida, was an important
nosocomial infection in this tertiary care hospital in Northeast Thailand. The mortality rate was
high, particularly in patients who were critically ill. Rapid diagnosis and early treatment are
therefore important challenges for improving clinical outcomes.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
The incidence of nosocomial fungemia, most frequently as a
result of Candida spp and on a some occasions as a result of§ This study was presented in part at the 13th International Con-
gress on Infectious Diseases, Kuala Lumpur, Malaysia, 19—22 June,
2008 (final abstract number 45.005).
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doi:10.1016/j.ijid.2008.04.009Trichosporon spp, has dramatically increased in recent dec-
ades.1 The increased incidence has been attributed to
advances in modern medicine, e.g., organ transplantation,
chemotherapeutic agents, invasive monitoring devices, par-
enteral nutrition, broad-spectrum antimicrobial agents, and
assisted ventilation, all of which prolong survival but put
patients at high risk of infection.
Fungemia has become a major cause of morbidity and
mortality in hospitalized patients, and many studies have
repeatedly identified the common independent risk factorsPublished by Elsevier Ltd. All rights reserved.
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motherapy, previous fungal colonization, indwelling catheter-
ization, neutropenia, and hemodialysis.1 However, several risk
factors are still debated, such as corticosteroid treatment,
underlying malignancy, parenteral nutrition, surgery, assisted
ventilation, intensive care unit stay, and malnutrition.
Themortality rate among patients with fungemia has been
found to be high, ranging between 50% and 80%.1—5 Apart
from the high mortality rate, there is concern that there has
been a change in the epidemiology of candidemia, from
Candida albicans infection to non-albicans Candida infection,
specifically Candida parapsilosis, Candida glabrata, Candida
tropicalis, and Candida krusei. Several studies have demon-
strated the clinical importance of both C. glabrata and C.
krusei as an emerging problem in association with the intro-
duction of fluconazole prophylaxis.6—9 High acute physiology
and chronic health evaluation (APACHE) II scores, inadequate
initial therapy, lack of antifungal therapy, and failure to
remove central venous catheters were consistently identified
as independent risk factors influencing mortality in fungemic
patients, but the other factors (e.g., species of Candida,
timing of initiation of antifungal treatment) remain
unclear.2,5,10
In Thailand, the data related to fungemia are limited,
therefore, we conducted a retrospective study to evaluate
the incidence, risk factors, causative fungi, and outcomes of
fungemia in adult, non-HIV-infected patients admitted to a
tertiary care hospital in Northeast Thailand over five con-
secutive years.
Materials and methods
Between 1999 and 2003, all non-HIV-infected patients with
fungemia, aged over 15 years, were identified through the
records of the clinical microbiological laboratory at Srina-
garind Hospital, a tertiary care, 760-bed, university hospital
located in Northeast Thailand. The medical records of the
identified patients were reviewed to recruit the study
patients. Patients were included into the study if they had
evidence of sepsis with at least one positive blood culture
containing either Candida or Trichosporon.
Demographic data, the potential risk factors for developing
fungemia presenting within 30 days prior to the diagnosis of
fungemia, and outcomes were retrieved from the medical
records. The following data were recorded: age, sex, type
of infection (community-acquired vs. nosocomial infection
following the definitions of the Centers for Diseases Control
and Prevention), admission ward at onset of fungemia, co-
morbiddiseases/conditions, durationofhospitalizationbefore
contracting fungemia, assisted ventilation, bacteremia,
broad-spectrum antibiotic therapy, prior antifungal prophy-
laxis or treatment, fungal colonization, indwelling central
venous catheterization or Foley’s catheter, treatment with
corticosteroid (20 mg/day for >1 week), parenteral nutri-
tion, surgical procedures, neutropenia (neutrophils <0.5 
109 cells/l), prolonged hospitalization (>30 days prior to the
onset of candidemia), and stay in the intensive care unit (ICU).
The severity of infection and concomitant bacteremia were
also evaluated. Severity of illness was estimated using the
APACHE II score on the day of positive blood culture or within 5
days of positive blood culture if the data were unavailable.
Concomitant bacteremia was defined as the isolation ofbacteria from the blood within 24 hours of the initial positive
fungal culture.
Factors related to mortality in these patients, including
age,presenceof sepsis or septic shock,APACHE II score, steroid
treatment, exposure to antimicrobial agents, parenteral
nutrition, assisted ventilation, neutropenia, concomitant bac-
teremia, indwelling central venous catheterization, type of
fungemia (primary vs. secondary fungemia), type of fungus (C.
albicans vs. non-albicans Candida vs. other yeasts), and anti-
fungal therapy were evaluated. The study protocol was
approved by the Institutional Review Board of Khon Kaen
University.
Blood cultures were processed using BacTAlert automated
culture system following the manufacturer’s instructions.
Fungal isolates that formed chlamydospores were identified
as C. albicans; further species identification was performed
using sugar fermentation and assimilation characteristics
based on standard methods.
Statistical analysis
Data analyses were performed using SPSS version 11.5 (SPSS
Inc., Chicago, IL, USA). To compare categorical variables, the
Fisher’s exact or Pearson’s Chi-square tests were used as
appropriate. The Wilcoxon and Kruskal—Wallis tests were
used to test for statistical significance of the continuous
variables as none of them were normally distributed. A p-
value of <0.05 was considered statistically significant.
The parameters related to mortality were evaluated using
a univariate analysis. All variables significantly associated
with death on the univariate analysis were included in the
multiple logistic regression analysis, using the backward
likelihood ratio selection method. The results of the final
model are presented as odds ratios (OR) with 95% confidence
intervals (95% CIs).
Results
During the 5-year period, there were 147 episodes in 142
patients of positive blood culture for either Candida (138
episodes, 93.9%) or Trichosporon (nine episodes, 6.1%). Among
the 138Candida isolates, themost commonwasC. parapsilosis
(40 episodes, 29.0%), followed by C. albicans and C. tropicalis
(37 episodes each, 26.8%). C. krusei, C. glabrata, Candida
stellatoidea, andCandidarugosawere isolated in twoepisodes
each. The remaining 16 isolated blood cultures grew Candida,
but species identification was not performed. The trend and
distribution of fungi causing bloodstream infection are pre-
sented in Figure 1. The overall incidence of fungemia was 14.1
per 10 000 hospital admissions.
The medical records were available for 86 cases (58.5%).
Of these, four cases were considered as contamination (two
cases of Trichosporon isolates and one case each of C. rugosa
and Candida species isolates) because of lack of clinical
sepsis and presence of only one positive blood culture; these
were then were excluded from the study. The demographic
data of the remaining 82 patients are summarized in Table 1.
The median age of these patients was 57 (range 16—85) years
and approximately 2/3 were male. The majority of patients
had underlying, predisposing diseases (75 cases, 91.5%): 21
cases (25.6%) of solid tumors, 15 (18.3%) of diabetes mellitus,
13 (15.9%) each of gastrointestinal/hepatobiliary diseases
Figure 1 Trend and distribution of fungi causing bloodstream
infection (N = 147).
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cancer/diseases, and six (7.3%) of cardiovascular diseases.
The median duration of hospitalization prior to contracting
fungemia was 16.5 (range 0—163) days. Themedian APACHE II
score was 19 (range 2—42).
All patients had at least one risk factor for developing
fungemia, including indwelling Foley’s catheter (53 cases,
64.6%), assisted ventilation (45 cases, 54.9%), central venous
catheterization (44 cases, 53.7%), prior surgery (41 cases,
50%), prior ICU hospitalization (38 cases, 46.3%), fungal
colonization (25 cases, 35.4%), prior abdominal surgery (28
cases, 34.1%), received parenteral nutrition (27 cases,
32.9%), received steroid treatment (20 cases, 24.4%), pro-
longed hospitalization (19 cases, 23.2%), received invasive
procedure (15 cases, 18.3%), recent bacteremia (12 cases,
14.6%), and neutropenia (11 cases, 13.4%). All except two
cases in patients with non-albicans candidemia had had prior
antimicrobial therapy. The two most common classes of
exposed antibiotic prior to developing fungemia were cepha-
losporins (56 cases, 70%) and aminoglycosides (37 cases,
46.3%).
Among the 82 cases, 54 (65.9%) and 23 (28.0%) patients
had non-albicans candidemia and C. albicans candidemia,
respectively. C. tropicalis (22 cases) and C. parapsilosis (21
cases) were the two most common isolates among those with
non-albicans candidemia. The remaining five patients (6.1%)
had fungemia from Trichosporon species. The demographic
characteristics and risk factors for developing fungemia
among these three groups of patients were not significantly
different except for prior bacteremia ( p = 0.03) and pre-
sence of fungal colonization ( p = 0.04). Prior bacteremia and
presence of fungal colonization were significantly more com-
mon in patients with C. albicans candidemia than those with
non-albicans candidemia (7/23 cases (30.4%) vs. 4/54 cases
(7.4%); p = 0.01, and 13/23 cases (56.5%) vs. 15/54 cases
(27.8%); p = 0.02, respectively). Three cases in patients with
non-albicans candidemia and one case in those with Trichos-
poron fungemia had received prior systemic anti-fungal
therapy, but none of those with C. albicans candidemia
had done so.The overall in-hospital mortality rate was 56.1%. Fifty-one
cases (62.2%) received systemic antifungal treatment with
either amphotericin B deoxycholate or fluconazole. Of these,
11 cases (21.6%), 13 cases (25.5%), 6 cases (11.8%), and 21
cases (41.2%) started antifungal treatment within 24 hours,
24—48 hours, 48—72 hours, and >72 hours of positive blood
culture, respectively. The mortality rate was not significantly
different between patients who received antifungal treat-
ment and those not treated (29/51 cases (56.9%) vs. 17/31
cases (54.8%); p = 0.86).
In the univariate analysis, the factors significantly asso-
ciated with death were the presence of septic shock (OR
10.93, 95% CI 2.33—51.19), higher APACHE II score (OR 1.16
per 1-point increments, 95% CI 1.07—1.26), having received
prednisolone 20 mg/day or other steroid with equivalent
dose (OR 4.27, 95% CI 1.28—14.22), and assisted ventilation
(OR 8.50, 95% CI 3.12—23.13) (Table 2).
In the multivariate analysis, three factors were related to
mortality in the studied patients, including high APACHE II
score (OR 1.12 per 1-point increments, 95% CI 1.03—1.23),
assisted ventilation (OR 3.49, 95% CI 1.04—11.64), and neu-
tropenia (OR 7.47, 95% CI 1.25—44.74).
Discussion
The incidence of nosocomial fungal infections has increased
in recent years and this has raised concerns because it is
associated with substantial mortality andmedical costs.1 The
overall incidence of fungemia among non-HIV-infected, adult
patients in our institution was also high and had a major
impact on mortality, as 56% of patients died. The majority of
nosocomial fungal infections (approximately 80%) are report-
edly caused by Candida spp, and these organisms are the
predominant fungi isolated from patient blood.
In our present study, Candida causing bloodstream infec-
tions accounted for 93.9% of fungemia. Non-albicans Candida
causing fungemia, particularly C. parapsilosis and C. tropi-
calis, predominated. The uncommon, difficult-to-treat
yeasts causing fungemia, Trichosporon, have raised concerns
at our institution although they presented in only a small
proportion (6.1%) of the cases, because their clinical features
could not be distinguished from fungemia due to Candida.
Similarly, in another retrospective study conducted at a
different university hospital in Thailand, Jutivorakool et al.
found that the incidence of candidemia caused by non-albi-
cans Candida (55.7%) tended to be higher than that for C.
albicans. Data on the predominant species of non-albicans
Candida in their study, however, were limited because spe-
cies identification was performed on only 12.2% of non-
albicans Candida.11
Between 1999 and 2000, the incidence of C. parapsilosis
at our institution was remarkable; outbreak occurrence, the
increase in use of central venous catheters, and parenteral
nutrition were suspected. The retrospective nature of our
study limits the investigation of these possibilities. Not hav-
ing a fluconazole prophylaxis recommendation at our institu-
tion could be the reason why there has not been an emerging
problem of C. glabrata or C. krusei as seen in many other
institutions.6,12,13
Underlying and/or pre-existing diseases are commonly
present in patients with fungemia; indeed, these affected
up to three-quarters of the patients in our present study.
Table 1 Demographic data and risk factors for fungemia in the patients (N = 82)









Median age, years (range) 61 (21—85) 57 (16—77) 42 (19—52) 57 (16—85) 0.05
Male 15 (65.2) 33 (61.1) 1 (20.0) 49 (59.8) 0.16
Nosocomial infection 20 (87.0) 49 (90.7) 4 (80.0) 73 (89.0) 0.71
Admission ward at the onset of fungemia 0.68
Surgical ward 10 (43.5) 19 (35.2) 1 (20.0) 30 (36.6)
Medical ward 6 (26.1) 19 (35.2) 3 (60.0) 28 (34.1)
ICU 7 (30.4) 16 (29.6) 1 (20.0) 24 (29.3)
Underlying diseases 22 (95.7) 48 (88.9) 5 (100.0) 75 (91.5) 0.49
Solid malignancy 6 (26.1) 14 (25.9) 1 (20.0) 21 (25.6) 0.96
Diabetes mellitus 4 (17.4) 11 (20.4) 0 (0.0) 15 (18.3) 0.53
Gastrointestinal/hepatobiliary diseases 6 (26.1) 6 (11.1) 1 (20.0) 13 (15.9) 0.25
Chronic kidney disease/stone 4 (17.4) 9 (16.7) 0 (0.0) 13 (15.9) 0.60
Hematologic malignancy/diseases 3 (13.0) 7 (13.0) 1 (20.0) 11 (13.4) 0.91
Cardiovascular diseases 3 (13.0) 3 (5.6) 0 (0.0) 6 (7.3) 0.42
Other 5 (21.7) 7 (13.0) 2 (40.0) 14 (17.1) 0.24
Associated risk factors
Steroid treatment 6 (26.1) 12 (22.2) 2 (40.0) 20 (24.4) 0.66
Prior ICU hospitalization 14 (60.9) 22 (40.7) 2 (40.0) 38 (46.3) 0.26
Indwelling Foley’s catheter 18 (78.3) 33 (61.1) 2 (40.0) 53 (64.6) 0.18
Central venous catheterization 15 (65.2) 28 (51.9) 1 (20.0) 44 (53.7) 0.17
Parenteral nutrition 7 (30.4) 17 (31.5) 3 (60.0) 27 (32.9) 0.41
Prior surgery 15 (65.2) 24 (44.4) 2 (40.0) 41 (50.0) 0.22
Prior abdominal surgery 7 (30.4) 20 (37.0) 1 (20.0) 28 (34.1) 0.68
Prolonged hospitalization 6 (26.1) 13 (24.1) 0 (0.0) 19 (23.2) 0.70
Prior bacteremia 7 (30.4) 4 (7.4) 1 (20.0) 12 (14.6) 0.03
Assisted ventilation 15 (65.2) 28 (51.9) 2 (40.0) 45 (54.9) 0.44
Fungal colonization 13 (56.5) 15 (27.8) 1 (20.0) 29 (35.4) 0.04
Neutropenia 1 (4.3) 9 (16.7) 1 (20.0) 11 (13.4) 0.36
Invasive procedure 7 (30.4) 8 (14.8) 0 (0.0) 15 (18.3) 0.15
Median APACHE score (range) 19.5 (8—38) 19 (2—42) 16 (3—21) 19 (2—42) 0.31
Median duration of hospitalization
prior to fungemia, days (range)
19 (0—44) 15 (0—163) 18 (0—29) 16.5 (0—163) 0.77
Death 16 (69.6) 28 (51.9) 2 (40.0) 46 (56.1) 0.27
ICU, intensive care unit; APACHE, acute physiology and chronic health evaluation.
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diabetes mellitus, gastrointestinal/hepatobiliary diseases,
chronic kidney diseases, and hematological cancer/dis-
eases were common underlying diseases.1,6,14—16 The most
common predisposing factors for contracting fungemia in
our present study included the use of Foley’s catheter or
central venous catheter, receipt of steroid treatment or
parenteral nutrition, use of broad-spectrum antibiotics,
assisted ventilation, prior surgery or invasive procedure,
prior ICU hospitalization, prior presence of fungal coloni-
zation, prolonged hospitalization, recent bacteremia, and
neutropenia.
The importance of specific Candida species as an inde-
pendent factor of death in candidemic patients has been the
subject of controversy. Studies conducted by Alonso-Valle
et al. and Weinberger et al., showed a negative impact of C.
albicans on outcome compared to non-albicans Candida.5,17
The crude mortality rate associated with C. parapsilosisinfection has been lower than that reported for invasive
infection with C. albicans or other non-albicans Can-
dida.18—20 C. glabrata candidemia may lead to an increased
risk of mortality because of its lower susceptibility to anti-
fungal agents; however Klevay et al. found that there was no
difference in mortality rate between C. albicans and C.
glabrata bloodstream infection.21 In our study, we did not
find either C. albicans or other non-albicans Candida species
to be more associated with fatal outcome in these candi-
demic patients.
Several studies have demonstrated the importance of
empirical antifungal therapy for patients suspected of hav-
ing invasive candidemia, to improve survival and shorten
hospitalization.2,5,22—25 Lack of antifungal therapy has been
demonstrated as an independent factor related to death in
many studies; however this factor did not affect mortality
in our study, which accords with results from the study
conducted by Malani et al.26 Failure to demonstrate the
Table 2 Factor associated with mortality in patients with fungemia by univariate and multivariate analysis
Variables No. of deaths /
No. of patients
Univariate analysis Multivariate analysis
Crude OR 95% CI Adjusted OR* 95% CI
Age, 1-point increments 46/82 1.00 0.97—1.02 - -
APACHE II score, 1-point increments 46/82 1.16 1.07—1.26 1.12 1.03—1.23
Sepsis 1.29 0.08—21.29 - -
Yes 45/80
No 1/2
Septic shock 10.93 2.33—51.19 - -
Yes 18/20
No 28/62
Received steroid 20 mg/day
Yes 16/20
No 30/62 4.27 1.28—14.22 - -
Received parenteral nutrition 0.99 0.39—2.56 - -
Yes 14/25
No 32/57
Prior antimicrobial therapy 2.65 0.23—30.41 - -
Yes 45/79
No 1/3
Assisted ventilation 8.50 3.12—23.13 3.49 1.04—11.64
Yes 34/43
No 12/39
Neutropenia 3.58 0.71—18.03 7.47 1.25—44.74
Yes 8/10
No 38/72
Concomitant bacteremia 1.05 0.22—5.01 - -
Yes 4/7
No 42/75
Retained central venous catheter 3.06 0.68—13.79 - -
Yes 14/18
No 8/15
Type of fungemia - -
Primary fungemia 32/53 1
Secondary fungemia 14/29 0.61 0.25—1.53
Type of fungus - -
C. albicans 16/23 1
Non-C. albicans 28/54 0.45 0.16—1.28
Other yeasts 2/5 0.44 0.05—3.76
Time to starting antifungal therapy - -
Within 24 hours 8/11 1 0.11—3.40
24—48 hours 8/13 0.60 0.05—3.00
48—72 hours 3/6 0.38 0.07—1.65
>72 hours 10/21 0.34
Lack of antifungal therapy 0.92 0.38—2.26 - -
Yes 17/31
No 29/51
* Factors adjusted in the multivariate analysis included APACHE (acute physiology and chronic health evaluation) II score, septic shock,
assisted ventilation, received prednisolone >20 mg/day, type of fungus, and neutropenia.
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many confounders contributing to the cause of death in
these patients or rapidly fatal illness in the course of
infection.As with several other studies, our present study shows that
a high APACHE II score, assisted ventilation, and neutropenia
are significantly associated with hospital mortality in these
patients.2,14,27 Patients with candidemia commonly had
Fungemia in non-HIV-infected patients 95co-morbidities and were critically ill. Prolonged neutropenia
compromises the host defense mechanism against both bac-
terial and fungal infections. These factors are more likely to
have the greatest impact for a grave prognosis among these
patients.
Our study had several limitations. The major, very impor-
tant limitation was the availability of medical records; these
were available for only about half of the cases, and this could
have caused a selection bias and distorted the outcomes of the
study. Therefore, interpretation of the results should be done
with extreme caution, and further well-defined studies are
needed to confirm these outcomes. Secondly, we were unable
toassess the reason foremergenceof non-albicans candidemia
in our setting. The retrospective nature of the study and the
small sample size are major constraints. Finally, antifungal
susceptibility was not performed in our institution so we could
not evaluate whether the presence of antifungal resistance
was an issue and might have affected mortality.
In summary, we have demonstrated the significance of
candidemia as a cause of nosocomial infection and its sig-
nificant impact on mortality at a tertiary care hospital in
Northeast Thailand. Non-albicans Candida is a major con-
tributor in our setting. Rapid diagnosis, reduction of severity
in patients, and early empirical antifungal treatment in the
high-risk groups are the challenges for improving clinical
outcomes.
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